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DEPOT DIFFERENCES IN ADIPOKINE SECRETION FROM HUMAN 
OMENTAL AND ABDOMINAL SUBCUTANEOUS ADIPOSE TISSUES: 
POTENTIAL ROLE OF ADIPOREDOXIN 
STEFANIE KNEBUSCH TORIELLO  
ABSTRACT 	  
 Adiporedoxin (Adrx) is an adipose tissue specific protein discovered by the Pilch 
lab. It is a member of the peroxiredoxin family and localized in the endoplasmic 
reticulum (ER). Previous studies showed that Adrx is involved in ER redox regulation 
and disulfide bond formation and secretion of adipokines. Further,  Adrx mRNA 
expression and protein levels in human abdominal adipose tissue of young, healthy 
subjects, ranging in levels of obesity, correlated positively with adiponectin mRNA and 
protein, and negatively with adipose tissue inflammation (as indicated by phospho-Jun 
kinase).  
Since previous studies have shown depot differences in adipokine release, we 
wanted to determine the differences in Adrx expression in human adipose tissues depots. 
There are no data on depot differences in Adrx expression and its association with 
adipokine release from human adipose tissue.  
It is well known that omental (Om) adipose tissue is more inflamed and secretes 
higher amount of interleukin-6 (IL-6) while secreting lower amount of leptin than 
abdominal subcutaneous (Abdsc) fat. depot.  Reports on depot differences in adiponectin 
secretion are inconsistent.  Adipokine release measured from fresh obtained adipose 
tissues during a short-time incubation reflects a more physiologic state and the 
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characteristics of the subjects compared to cultured cells and thus, we measured the rates 
of adipokine secretion during acute incubation.  
Adiponectin is an insulin-sensitizing protein, exclusively produced by mature 
adipocytes and highly expressed in by adipose tissue. The native adiponectin exists as 
low molecular weight, middle-molecular weight and high molecular weight (HMW).The 
potency of adiponectin is linked to the HMW isoform. There are no previous reports on 
the secretion of adiponectin isoforms from human Om and Abdsc adipose tissues. 
In this study the goal is to determine the depot differences in Adrx expression and 
adipokine release in human Abdsc and Om adipose tissue in obese and morbidly obese 
subjects and to determine the relationship between Adrx protein expression and 
adipokine release in Abdsc versus Om and circulating levels of adipokines, primarily 
total and HMW adiponectin. To determine whether Adrx expression is correlated in the 
release in adipose tissue and secretion of circulating adipokines.    
Adrx protein levels (assessed by Western blot) were ~72% higher in Abdsc than 
Om (p<0.05; paired t-test values).  As expected, secretion per gram of tissue in 3hr 
incubation of total adiponectin (~ 55%) and leptin (~134%) was higher, and IL-6 
secretion was lower (~56%) in Abdsc compared to Om.  Total adiponectin secretion 
measured with quantitative Western blotting, is higher in Abdsc by 19% compared to 
Om. However, HMW adiponectin by 29% and % HMW are higher by 30% in Om.   
Adrx protein levels were positively correlated with total adiponectin and HMW 
release in Abdsc and only with HMW in Om. Adrx levels were negatively correlated with 
% HMW release in Abdsc but not in Om. Since in Adrx KO mice presented lower total 
	  	   vii 
adiponectin in circulation, it was hypothesized that Adrx were positively correlated with 
circulating adiponectin, and wanted to study the correlation with serum adipokines. Adrx 
protein levels in Abdsc showed no correlation with total circulating adiponectin levels 
(ng/ml measured by ELISA) and a positive trend in Om.  Total serum adiponectin, HMW 
and  %HMW by Western blot showed no correlation with Adrx levels in both Abdsc and 
Om. None of the correlations with Adrx and adipokines in serum were statistically 
significant possibly due to a small sample size. 
These data suggest that depot differences in Adrx expression may influence depot 
differences in adipokine secretion. The mechanism of higher HMW adiponectin secretion 
in Om with low Adrx levels needs further study. 
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INTRODUCTION 	  
Obesity is a major public health problem in the United States. The prevalence of 
childhood and adult obesity in the United States and worldwide has increased 
dramatically in recent years and remains high, reaching 16.9% in youth and 34.9% in 
adults in the United States in 2011-2012.1 Overweight and obesity are positively 
associated with risk for chronic diseases such as type 2 diabetes and heart disease.  
Obesity increases risk of high blood pressure, stroke, nonalcoholic fatty liver disease, 
osteoarthritis, some types of cancer, including breast, colon, endometrial and kidney, 
leading to high mortality rates. 1-6  
Fat distribution is independently associated with metabolic diseases. A central fat 
distribution, a large waist due to accumulation of visceral and abdominal subcutaneous 
(Abdsc) fat, is classified as android (apple-shape) and is associated with higher metabolic 
disease risk.  In contrast, accumulation of gluteal-femoral fat gynoid (pear-shape) is 
associated with lower risk. Therefore to decrease the rates of type 2 diabetes and 
cardiovascular disease (CVD) it is important to determine the mechanisms associated 
with fat distribution and the development of metabolic diseases in obesity. 6,7,8,9   	  
Endocrine functions of adipose tissue 
Adipose tissue is a highly active metabolic and endocrine organ.  Adipocytes 
express and secrete various types of bioactive molecules, well known as adipokines. The 
adipokines establish an important role of adipose tissue as an endocrine organ that is 
involved in the integration and coordination of a variety of biological processes including 
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energy metabolism, glucose and lipid metabolism, neuroendocrine function and immune 
function.9,10-12 
Adipokines can act in local (autocrine/paracrine) and systemic (endocrine) levels.  
The hormones leptin and adiponectin and acute phase response proteins including Serum 
Amyloid A1 (SAA) and Retinol Binding Protein 4 (RBP4), are produced in adipocytes. 
Tumor necrosis factor alpha (TNF-a), interleukin 6 (IL-6), monocyte chemoattractant 
protein 1 (MCP1), among others, are produced in non-adipocytes within the adipose 
tissue.  9,10, 11-13 
Leptin and adiponectin play a role in appetite and satiety, fuel metabolism, innate 
immune function and reproduction. Leptin is a cytokine that provides signals to the 
organism regarding the energy status, especially fat stores, in the body. Leptin regulates 
appetite and satiety, food intake, energy expenditure and reproduction.12,14 Adiponectin 
plays a role as an insulin sensitizer predominantly in the liver and has anti-inflammatory 
and anti-apoptotic actions, so is anti-atherogenic. 12,15,16,19 The proinflammatory 
cytokines, TNFα and IL-6, have paracrine effects on adipocyte metabolism and endocrine 
function. Both may link obesity and insulin resistance. 13,17-19 IL-6 can impair insulin 
action on target tissues, by decreasing the insulin effects on glucose uptake into skeletal 
muscle and hepatic glucose output.13  
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Regulation of adipokine expression.   
Leptin levels are variable depending on sex, depot and positively associated with 
fat mass and percentage of body fat, body mass index (BMI) and circulating 
inflammatory markers. 12, 14, 34 Leptin levels are higher in women than men and increase 
with weight gain. Serum leptin is usually elevated in obesity within a wide range. Maffei 
et al, 1995, found that in humans at each BMI category, there was variability in plasma 
leptin levels suggesting that there are differences in its secretion rate from fat. He 
mentions, “leptin levels secretion has different mechanisms other than absolute fat mass 
per se”. 35 
Serum adiponectin levels are decreased in obesity and inversely correlated to 
systemic oxidative stress. Reactive oxygen species (ROS) exposure in adipocytes 
suppresses adiponectin mRNA expression and secretion and increases the mRNA 
expression of pro-inflammatory cytokines, IL-6 and MCP-1. Oxidative stress may play a 
role in reducing adiponectin levels production that can contribute to obesity-associated 
disease pathogenesis. 21 
In obesity, oxidative stress contributes to a vicious cycle that promotes increased 
inflammation in adipose tissue. Macrophage infiltration into adipose tissue (AT) 
increases the production of inflammatory cytokines.  Cell culture studies show that 
inflammatory cytokines, possibly through ROS production, may decrease expression of 
adiponectin and therefore are hypothesized to contribute to the lower adiponectin 
expression in obesity.  
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Depot differences in the endocrine function  
Subcutaneous and visceral adipose tissue depots are well characterized due to 
their differential contribution to metabolic diseases. 6,9 Adipose tissue depots present 
unique adipokine expression and secretion profiles. Visceral adipose tissue is associated 
with increased risk of metabolic diseases due to the differences in the endocrine function 
among adipose tissue depots. 
Adipocyte size varies between abdominal subcutaneous and visceral adipose 
tissue. During weight gain adipocytes can be generated more rapidly in some depots: 
Abdsc fat provides more long-term nutrient storage because it increases in fat cell 
number first and then in fat cell size. Omental depot increases in fat cell size rather than 
number. Also, the number of macrophages in omental is higher compared to 
subcutaneous adipose tissue, being one of the reasons why there is an increased 
production of cytokines from this depot but other stromal cells may also contribute.  
(Table 1) 
The levels of proinflammatory cytokines and anti-inflammatory cytokines are 
variable depending on fat depot and obesity. It is well known that proinflammatory 
cytokines, such as tumor necrosis factor (TNF-α) and IL-6 are secreted at higher levels 
while anti-inflammatory cytokines, like adiponectin and IL-10, are lower in obese vs lean 
individuals, and in visceral compared to subcutaneous depot. 13 A study by Fontana et al 
(2007) determined arteriovenous concentration differences across visceral fat, by 
obtaining portal vein and radial artery blood samples.46 They concluded that IL-6 
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concentration in omental adipose tissue is an important site for IL-6 secretion. These data 
measured in vivo by ELISA in Abdsc and omental are more physiologically relevant 
compared to other studies that measure secretion of IL-6 in longer time ex vivo 
incubations.46  
Subcutaneous adipocytes secrete higher levels of leptin and present higher levels of 
leptin mRNA compared to omental adipocytes. 34 Russel et al (1998) investigated leptin 
secretion in incubation medium (incubated in M199 + 1% BSA for 3 hr) of omental and 
Abdsc fat in severely obese women and men. Leptin secretion was measured with RIA 
and was 2 fold higher in subcutaneous than omental tissue expressed as ng/ 106 
cells/3hr.34,44  As well in other study,  Harmelen et al (1998) analyzed leptin secretion 
(ng/g/2hr incubation) in Abdsc and omental fat in obese and nonobese subjects. They 
found that leptin secretion were 2-3 times higher in subcutaneous than omental and per 
fat cell and the values were positively correlated with BMI.45   
The secretion of adiponectin by fat depot, visceral and subcutaneous, presents 
inconsistent results and is unclear. 16 The study by Kovacova et al, showed no significant 
difference in the secretion of total adiponectin in omental and abdominal subcutaneous 
adipose tissue explants (4 hr incubation in Krebs/Ringer phosphate buffer with BSA) 
measured by Western Blot.31 Drolet et al, measured total adiponectin release in Abdsc 
and omental in 2 hour incubation (Krebs/Ringer/Henseleit buffer) expressed in ng/ mg 
lipids and showed not significantly difference between depots.35 Motoshima et al, showed 
that in conditioned media samples for 12 and 24 hr basal adiponectin secretion was not 
significantly different between omental and Abdsc fat cells. 36 The study by Perrini et al, 
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determined total adiponectin releases in human omental and subcutaneous fat (incubated 
for 2h) and concluded that omental release higher adiponectin levels than subcutaneous, 
while adiponectin mRNA expression was higher in subcutaneous than omental by 
quantitative real-time PCR.37  In the study by Swensson et al, total adiponectin release 
measured by ELISA was higher in Abdsc than omental at different time points of 
incubation in M199-1% BSA (2h, 4h, 6h)47.  
Since the data on total adiponectin secretion are inconsistent, this study focuses in 
the secretion of adipokines in subcutaneous vs omental fat. In addition, there is no report 
on the depot differences in the release of adiponectin multimers. Thus, we also measured 
HMW, MMW, and LMW adiponectin levels with quantitative Western blotting. It is 
known that the expression of adiponectin is regulated by proinflammatory cytokines, 
TNF-α and IL-6, which suppress adiponectin production. In obesity adiponectin 
production are downregulated and proinflammatory cytokines are upregulated. 17,30 IL-6 
secretion rates as well as pJNK levels in adipose tissue were determined to assess the 
inflammatory states.  
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Table 1. Depot differences in adipokine production  
Adipokine Depot Sex 
differences 
Obesity Reference 
Leptin 
Subcutaneous > 
omental 
Women > men Increase 
Russell et al (1998) 
Harmelen et al 
(1998) 
Adiponectin 
 
Subcutaneous > 
omental 
Women > men 
Decrease 
 
Swensson et al 
No differences 
between depots 
Motoshima et al 
(2002) 
Kovacova et al 
(2011) 
Drolet et al (2009) 
Omental > 
Subcutaneous 
Perrini et al (2007) 
IL-6 
Visceral > 
subcutaneous 
 Increase Fontana et al (2007) 
 
Adiponectin production is downregulated in obesity 
Adiponectin is an endocrine factor released exclusively by mature adipocytes and 
highly secreted by adipose tissue. 12,15,31,32 In obesity, the circulating levels of adiponectin 
are decreased. It is well known that adiponectin plays a role as insulin sensitizing 
predominantly in the liver, has anti-inflammatory, anti-apoptotic protein on various 
different cell types and is anti-atherogenic. 12,15,16   
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The native adiponectin exist as low-molecular weight trimmers (LMW), middle-
molecular weight hexamers (MMM) and high molecular weight multimers (HMW), 
which are composed by 12-18 monomers. 15,31-33 The formation of MMM and HMW is 
favored by the lumen of endoplasmic reticulum (ER) by the disulfide bonds formation 
between the trimmers.  These three are the major forms that circulate in plasma. 16,32   
The adipocytes are the major determining factor that influences the production and 
secretion of the isoforms. 33   
The potency of adiponectin is linked to high molecular weight (HMW) isoform. 
The major biological effects of HMW are on liver, muscle and endothelium. 15, 32 HMW 
isoform levels in plasma and the ratio of HMW to total adiponectin are associated with 
increased glucose tolerance and insulin sensitivity rather than total adiponectin, 
suggesting that HMW is the active form of the protein. 15, 16, 32 
Total  and HMW adiponectin levels are higher in women compared to men.  
Meyer et al, found that serum total  and HMW adiponectin do not differ significantly 
between sexes but there is a tendency for being higher in females. Levels of both are 
decreased in obesity, which is related to conditions associated with insulin resistance, 
hyperlipidemia type 2 diabetes, atherosclerosis, nonalcoholic steatohepatitis (NASH) and 
metabolic disorders. 12,16,31, 32 
It has been previously shown that insulin-resistant obese subjects present low 
HMW and LMW levels compared to insulin-sensitive lean subjects.  Adipocyte size 
affects the secretion of adiponectin being meaningful to the metabolic and hormonal 
function of adipose tissue. 16    	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Adiporedoxin, a novel protein that may regulate adipokine secretion 
Adiporedoxin is a protein expressed at high levels in fat cells. The protein is 
present in the adipocyte endoplasmic reticulum and was found by Paul F. Pilch and his 
colleagues.38,39 Adiporedoxin is a member of the peroxiredoxin (Prx) family, redox-
regulated proteins, that its nominative activity is reduction of peroxides in various cell 
types.38 In previous studies, adiporedoxin has been reported as peroxiredoxin-like 2 
protein (PAMM) with the function of a redox regulatory protein in bone marrow 
monocyte that modulated osteoclast differentiation in vitro. 40 
Adiporedoxin and other proteins similar to Adrx are expressed in the ER.  
Alterations in adiporedoxin levels can affect proteins that contain disulfide bond such as 
adiponectin.38 In vitro, higher expression of adiporedoxin increases the secretion of 
adiponectin and vice versa.,39,40  
One study in mice found that adiporedoxin knockout (KO) mice present with 
reduced levels of circulating HMW adiponectin, increased intracellular adiponectin 
retention and normal glucose tolerance, mild hyperinsulinemia. 39When KO mice were 
fed on high fat diet for 6 weeks, they develop glucose intolerance/insulin resistance and 
present a further decrease in HMW adiponectin levels. KO mice were found to be free of 
fibrosis, apparently due to impaired collagen secretion. Wild type mice fed in a longer 
period of high fat diet showed decreased cellular adiporedoxin, and lower HMW 
adiponectin levels.  39,40 
Data from human preadipocytes show that during differentiation, adiporedoxin 
mRNA and protein are upregulated.39 It is shown in preliminary data in humans that 
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mRNA for adiporedoxin and adiponectin, and protein expression for adiporedoxin and 
adiponectin are positively correlated in both sexes, independent of BMI, which has an 
independent negative influence on adiponectin expression. 41 
Obese subjects present variation in the magnitude of inflammation of adipose 
tissues and insulin resistance that may affect adiporedoxin levels. In response to 
inflammation and to metabolic status of the adipose tissue in obesity, Adrx levels are 
down regulated, consequently decreasing adiponectin levels. A lower level of adiponectin 
in obesity may be one of various factors, which remain unknown. 41  
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Summary and Goals of the thesis: 
Studies by the Pilch and Fried labs indicate that Adrx is an important regulator of 
adipokine secretion.  Data from cell culture models shows that knockdown of Adrx in 
cultured human adipocytes decreases and overexpression increases the secretion of 
adiponectin.  However, no information was available on possible depot differences in 
Adrx expression, and whether it is associated with changes in adipokine release in intact 
human adipose tissue. Although studies document differences in the metabolism and 
endocrine function of Abdsc and Om depots of humans, data on adiponectin release are 
inconsistent and no previous studies measured the secretion of different adiponectin 
isoforms.  
 
Therefore the goals of the thesis were to: 
1. Determine the fat depot differences in adipokine release (adiponectin (total and 
HMW), leptin and IL-6) during short-term incubations of human Abdsc versus 
omental adipose tissues from obese subjects.   
2. Determine if Adrx expression differs between human Abdsc versus omental 
sample of obese and morbidly obese subjects, mostly females.   
3. Determine the correlation between Adrx protein expression and adipokine release 
from human Abdsc and omental adipose tissue. 
4. Determine the relationship between Adrx protein expression and circulating 
serum levels of adipokines, primarily of total and HMW adiponectin.  
. 
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METHODS AND PROCEDURES 
Subjects  
Participants were recruited from subjects undergoing elective surgery, such as 
laparoscopic sleeve gastrectomy, gastric bypass laparoscopic, nephrectomy donor 
laparoscopic and laparoscopic cholecystectomy. Adipose tissue samples were obtained 
from intra-abdominal (omental and mesenteric) and subcutaneous abdominal fat of a total 
of 44 samples from 35 females and 9 males that were selected for this study due to the 
availability of acute conditioned media samples, blood samples and fat tissue for protein 
expression.  
Each participant provided written informed consent.  The study was approved by 
the Institutional Review Board of the Boston University School of Medicine (Nutritional 
Regulation of Leptin Production, IRB Number H-28139). Information on the height and 
weight of volunteers, medications, medical conditions and serum levels of glucose, 
HbA1c, blood pressure were obtained from the medical records and recorded in lab 
records with a code number. 
 
Body Measurements 
On the day of the surgery, participants were given a consent form. Body measurements 
were obtained from the chart, weight and height, which were used to determine the body 
mass index (BMI) calculated as weight in kilograms divided by height in meters squared. 
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Blood Sampling 
Blood samples were taken on the day of the surgery in the overnight fasting state. Serum 
was separated with centrifugation for 15 min at 2500 rpm and 4 °C and stored at -80 OC 
for further analyses. Serum samples were used to measure glucose and insulin levels, and 
adipokines: leptin, total adiponectin and HMW adiponectin. 
 
Adipose Tissue Samples 
Fat tissue, Abdsc and omental, was excised in the operating room, and portions were 
immediately frozen in the operating room in liquid nitrogen or transferred to the lab in 
room temperature in media 199.  Frozen tissue was stored at -80 °C for later use.   
 
Measurement of Adipokine Secretion 
Adipokine Secretion 
Upon arrival in the laboratory, within 30 minutes of excision, adipose tissue samples, 
transferred in M199 were minced into 5 to 10 mg fragments with surgical grade scissors, 
rinsed with PBS, and incubated in M199 with 1% BSA for 3 hours with shaking 100 rpm 
at 37°C in duplicates (~100 mg in 1.5 ml incubation media).  After incubation, the media 
samples were collected and stored in aliquots at -80 OC for further analyses for adipokine 
secretion such as leptin, total adiponectin and IL-6.  	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Acute Media Analyses 
Leptin, IL-6 and adiponectin concentration was measured in acute media from adipose 
tissue using an enzyme-linked immunosorbent assay (ELISA). Standard and acute media 
measurements were performed in duplicate. A non-linear fit curve of the adipokine 
standards was performed to recalculate the adipokine concentration values using the 
Graphpad Prism 5.0b software.  
To measure samples within the range of the standard (Leptin: 0.5–1.5 ng/mL; 
adiponectin: 0.5–3 ng/mL, IL-6: 0.18-3 ng/ml) Abdsc and omental samples were used, 1 
and 1/2 dilution for leptin, 1/50 and 1/100 for adiponectin, 1/1.25 dilution and 1/2.5 in 
Abdsc and 1/2 and 1/4dilution in omental for IL-6 quantification. 
In acute samples the intra-assay coefficient of variation values were 9.0±0.7% for IL6 
and 9±1.5% for leptin. Adiponectin intra-assay coefficient of variation values were 
2±0.5%; 7±2.3%; and inter-assay coefficient of variation values were 5±1.4%.  
 
Acute media leptin levels: 
For detection of natural and Recombinant Human Leptin in serum, the samples were 
analyzed with DuoSet ELISA Development kit (Catalog # DY398 from R&D Systems) 
and the manufacturer’s instructions were followed (DuoSet ELISA, R&D Systems Inc, 
Minneapolis, MN). 
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Acute media total adiponectin and HMW levels: 
For detection of Human Total Adiponectin/Acrp30, acute samples were analyzed with 
Human Total Adiponectin/Acrp30 Quantikine ELISA Kit (Catalog DRP300 R&D 
Systems, Minneapolis, USA). 
For acute media Western Blot analysis was also performed to measure adiponectin 
multimers (description below). 
 
Acute media IL-6 levels: 
For detection of Human IL-6, the samples were analyzed with DuoSet ELISA Human IL-
6 (Catalog DY206 R+D Systems, Minneapolis, USA). 
 
Serum Hormone Measurements  
Standard and serum analysis measurements were performed in duplicates. 
 
Serum insulin levels: 
For detection of serum insulin concentration, the serum samples were analyzed by 
Ultrasensitive Insulin Enzyme-linked immunosorbent assay (ELISA) kit for the 
quantitative determination of insulin in serum and plasma (Catalog 80-INSHU-E01.1) 
and following the manufacturer’s instruction (ALPCO Diagnostics, Salem, NH). 
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Serum leptin levels: 
For detection of human leptin in serum, the samples were analyzed with DuoSet ELISA 
Development kit (Catalog # DY398 from R&D Systems) and the manufacturer’s 
instructions were followed (DuoSet ELISA, R&D Systems Inc, Minneapolis, MN). 
 
Serum total adiponectin and HMW levels: 
For detection of Human Total Adiponectin/Acrp30, serum samples were analyzed with 
Human Total Adiponectin/Acrp30 Quantikine ELISA Kit (Catalog DRP300 R&D 
Systems, Minneapolis, USA). For serum Western Blot analysis was also performed 
(description below). 
 
A non-linear fit curve of the adipokine standards was performed to recalculate the 
adipokine concentration values using the Graphpad Prism 5.0b software. 
To measure samples within the range of the standard (Leptin: 0.5–1.5 ng/mL; 
Adiponectin: 0.5–3 ng/mL, insulin ranges: 5 – 25 µIU/mL) serum samples were diluted 
1/100 for leptin, 1/5151 for adiponectin quantification and no dilution for insulin. 
The intra-assay coefficient of variation values were 9.9±4% for insulin, 6±3.9% for 
adiponectin and for leptin serum intra-assay coefficient of variation values were 
1.9±0.5%; 7.7±1.2%; and inter-assay coefficient of variation values were 4±0.9%. 
Fasting glucose levels were determined by YSI 2300 STAT Plus Glucose & Lactate 
Analyzer. Precision as specified in YSI 2300 Stat Plus Specification Sheet is ±2% or 2.5 
mg/L for glucose. 42 
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Western blot analysis of total adiponectin and HMW in serum and acute samples  
Adiponectin, high, medium and low molecular weight isoforms were measured in serum 
and 3 hr secretion media using native PAGE electrophoresis. The samples were thawed 
on ice. 6% PAGE gels were prepared (Tris-Acetate (23.6 ml of ddH20, 10 ml of Tris-
Acetate 1.5M, 6 ml of Acrylamide 40% 37:1, 400 µl of 10% APS and 48 µl of TEMED) 
and stacking solution 3% (7.94 ml ddH20, 0.78 ml of Acrylamide 40% 37:1, 0.78 ml Tris-
acetate, 100 µl of 10% APS and 16 µl of TEMED).  
Serum samples were diluted with PBS 100 times and mixed with native sample buffer 
(Life Technologies) and 10 µl were loaded per well.  30 µl acute media samples were 
mixed with 10 µl of native sample buffer and 20 µl of the mixture was loaded into each 
well. In each gel, control serum samples were loaded in 3 different amounts.  Protein 
samples were resolved with electrophoresis in Tris-Glycine running buffer (25 mM Tris 
Base, 190 mM glycine) and transferred to PVDF membranes (3 hours at 40 V).  
After transfer, membranes were blocked in 3% milk/ Tris Buffer Saline and 0.1% Tween 
20 (TBS/T) for 1 hr at room temperature and incubated with anti-adiponectin antibody 
(1/5000 in 3% BSA in TBS/T, BD Bioscience, Catalog # 611644) overnight at 4 oC.  The 
next day membranes were washed 3 times for 5 minutes in TBS/T and incubated with 
anti-mouse IgG, HRP-linked Antibody (1/6000, Cell Signaling Technologies, #7076) for 
1 hour at room temperature.  The membranes were washed three times with TBS/T, 5 
minutes each wash and used for signal detection with a highly sensitive enhanced 
substrate for detecting horseradish peroxidase (HRP) on immunoblots, SuperSignal West 
Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL). 
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Chemiluminescence images were captured using Luminescent Image Analyzer 
(LAS4000, Fuji) and band densities were quantitated using Multi Gauge Image software. 
Western Blot analysis in acute samples and serum samples were made in duplicate. The 
control was a pool of the samples that were run in each gel. The samples were normalized 
for each gel. 
 
Western blot analysis of adiporedoxin protein expression in adipose tissue  
Adipose tissue samples were homogenized with glass on glass tissue grinder (Kontes, 
Kimble Chase North America), in 3 times volume of lysis buffer (Cell Signaling 
Technology, Triton X-100 (polyethylene glycol octylphenol ether 1%, Danvers, MA) or 
(20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 
2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml 
leupeptin, catalog number 9803) with 15 strokes.  Homogenates were centrifuged for 10 
minutes, 14,000g at 4 °C and the internatant below the fat cake was used for Western 
blotting.  Internatant were mixed with LDS sample buffer (Life Technologies) and 
denatured by boiling for 5 minutes.  
For adiporedoxin measurement 10 µl of the sample was loaded in SDS-PAGE along with 
molecular weight markers. Gels were prepared as follows: 10% Tris-HCl (19.2 ml of 
ddH20, 10 ml of Tris-HCl 1.5M, 10 ml of Acrylamide 40% 29:1, 400 µl of 10% SDS, 
400 µl of 10% APS and 48 µl of TEMED) and stacking solution 3% (7.3 ml ddH20, 1.25 
ml of Acrylamide 40% 29:1, 1.26 ml Tris-HCl, 100 µl of 10% SDS, 100 µl of 10% APS 
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and 16 µl of TEMED). 3 different amounts of pooled adipose tissue lysates were run on 
each gel.  
After resolving in Tris/Glycine/SDS running buffer, protein samples were transferred to 
PVDF membranes (60 V for 100 minutes at 4 °C).  After transfer, membranes were 
blocked with 3% milk in TBS/T for 1 hour at room temperature. Membranes were then 
probed with the primary rabbit anti FAM213A antibody (1/1000, Sigma #HPA009025) 
and a loading control, HSP90 (1/2000, Santa Cruz Biotechnology, Cat sc-69703/ sc-
101494) overnight at 4°C. After overnight incubation, membranes were washed with 
TBS/T 3 times and incubated with anti-rabbit IgG-HRP antibodies (1/2000, Cell 
Signaling Technologies, Cat #7074) for 1h at room temperature, followed by 3 times of 
washing in TBS/T and signal detection with SuperSignal West Femto Maximum 
Sensitivity Substrate for adiporedoxin or West Pico Maximum Sensitivity Substrate for 
HSP90 (Pierce Biotechnology, Rockford, IL). Chemiluminescence images were captured 
using Luminescent Image Analyzer (LAS4000, Fuji) and band densities were quantitated 
using Multi Gauge Image software. Adrx levels were presented relatively to HSP90.   
Western Blot analysis in Adrx protein levels was made once in each depot and if samples 
were not well expressed or if the membrane presented contamination samples were 
excluded. The control was a pool of the samples that were run in each gel. The samples 
were normalized for each gel. 
  
	  20 
Fat cell size and number calculation: 
Adipocytes were isolated with collagenase digestion of adipose tissue [Type 1 
collagenase (Worthington Biochemicals), 1 mg/ml in modified Krebs Henseleit Buffer 
(KHB), pH 7.4, containing 4% bovine serum albumin and 5 mM glucose] at 37 °C for 1 
h.  The digest was filtered thought 250 micron mesh and adipocytes are washed by 
floatation or low speed centrifugation and then resuspended in buffer. Cells were sized 
after digital photography using imaging software (Image J, NIH). The mean fat cell 
volume was calculated according to Goldrick formula.43 The mean fat cell weight was 
calculated as fat cell volume multiplied by the density of triglycerides (0.915 g/ml).  The 
percentage of lipid in each fat depot was assessed by dividing lipid weight by wet tissue 
weight.  Total fat cell number was calculated as depot weight multiplied by percentage of 
lipid and divided by the mean fat cell weight.  
 
Statistical Analyses 
Paired t-tests were conducted using JMP Pro 11.2.1 to assess differences in the 
expression of adiporedoxin and adipokine secretion in human omental (Om) and 
abdominal subcutaneous (Abdsc) adipose tissues of this study. For the correlation 
between adiporedoxin (Adrx) and adipose tissue and serum adipokines, a bivariate 
correlation was used. A p-value less than 0.05 was considered to be statistically 
significant. The differences between depots were calculated in each paired samples and 
the average of all the samples was the differences between each depot in %.   
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RESULTS 
Subject characteristics 
 
 Forty-four samples were analyzed for the study, 80% were females (n=35) and 
20% (n=9) males. The study included 7 (F6 M1) African Americans, 24 (F19, M 5) 
Caucasian, and 13 (F10, M3) Hispanics (Table 2). 
20% from all subjects were classified as diabetic (9 subjects, 5 F: 4 M). Of the diabetic 
subjects, 4 were classified as ‘treated’ based on medications listed in the medical record 
and 4 of them were not taking any medication for diabetes at the time of surgery. HbA1C 
data were taken from the medical record prior to the surgery.  The characteristics of these 
subjects are shown in Table 3.  In 2 subjects, there was no blood sample available and 
insulin and glucose could not be determined. All the subjects were included in the 
analysis since excluding the diabetic subjects had no effect on the analysis. Subject 1 and 
9 are the same subject that had the same surgery 2 times in less than one year. In between 
the subject did loose weight, improved HbA1C and had new medications. The subject 
were included as two different persons.(Table 3).  
Table 2. Subject characteristics 
 
n Mean ± SD Range (av. range) SEM 
Age (years) 
 
44 39.8± 11.7 20-69 (49) 1.76 
BMI (kg/m2) 
 44 42.1± 6.8 25.6-57.5 (31.8) 1.02 
Glucose (mg/dl) 
 31 98.8± 50.1 70.1-341 (270.9) 9.0 
Insulin (µU/ml) 
 
31 8.5± 4.12 1.0-19.0 (18.0) 0.73 
HbA1C (%) 43 5.9± 1.5 4.6-12.6 (8.0) 0.22 
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Table 3. Characteristics of diabetic subjects 
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Adipokine secretion from human omental and Abdsc adipose tissues 
Higher leptin secretion in Abdsc than omental adipose tissues 
The rates of adipokine secretion were measured by incubating adipose tissue fragments in 
M199+1% BSA for 3 hours using fresh obtained tissue (within 30min of excision). 
Leptin levels in the incubation media was measured by ELISA (n=43).  As expected, 
leptin secretion from Abdsc, expressed as nanogram per gram of tissue for 3 hr 
incubation, was ~134% higher compared to omental adipose tissue (Figure 1A). Because 
fat cell size is known to affect leptin secretion and is lower in omental than Abdsc, we 
also calculated leptin release per cell. Leptin secretion, expressed as ng/million fat 
cells/3h, was 3 fold higher in Abdsc than omental adipose tissue (Figure 1B).  
 
Figure 1. A. Leptin release (ng/g/3hr) from forty-three paired samples in omental (Om) and 
abdominal subcutaneous (Abdsc). B. Leptin release (ng/106 fat cell/3hr) from 22 paired 
samples in omental and Abdsc.  Fragments of adipose tissue were incubated for 3hr in 
M199+1% BSA pH 7.4 under 95% of Oxygen and 5% CO2. Leptin levels were determined 
with ELISA. *, p<0.05 Om vs. Abdsc with paired t test. 	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Higher Total adiponectin secretion in Abdsc than omental adipose tissues 
Total adiponectin release during the 3h incubation, expressed as nanogram per gram of 
tissue for 3 hr incubation was ~55% higher in Abdsc compared to omental adipose tissue.  
Because adiponectin expression is affected by fat cell size and fat cell size is different 
between Om and Abdsc, we calculated adiponectin release per cell in each depot. When 
adiponectin release was calculated per million fat cells, it was 1.8 fold higher in Abdsc 
than omental with p<0.001 (Figure 2). 
 
Figure 2. A. Total adiponectin release (ng/g/3hr) from forty-three paired samples in omental and 
abdominal subcutaneous adipose tissue. B. Total adiponectin release, expressed as ng/106 fat 
cell/3hr, from 22 paired samples in omental and Abdsc. Fragments of adipose tissue were 
incubated for 3hr in M199+1% BSA pH 7.4 under 95% of Oxygen and 5% CO2 and 
adiponectin levels were measured with ELISA. *, p<0.05 Om vs. Abdsc with paired t test. 	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Western analysis of the secretion of adiponectin multimers from Om and Abdsc 
adipose tissues 
Adiponectin circulates in multiple isoforms, high, medium and low molecular weight.  
The HMW form is of most interest because it is the most active, and its assembly requires 
intermolecular disulfide bonds and would therefore be expected to be impaired in adipose 
tissue with higher levels of inflammation. We therefore measured the release of 
adiponectin isoforms with Western Blotting in the same acute incubation samples (n=43). 
Total adiponectin, the sum of HMW, MMW and LMW, is significantly higher, by ~19%, 
in Abdsc (Figure 3A), similar to the results measured with ELISA.  The secretion of 
HMW adiponectin isoform, however, is ~29% higher in omental than Abdsc with a p 
value of 0.008 (Figure 3B).  Percent of HMW/total adiponectin secreted was also higher 
in omental by ~30% than Abdsc (p < 0.001) (Figure 3C). Representative images of native 
Western blotting are shown in Figure 4.  
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Figure 4: Representative images of Western blotting Native PAGE gels 3 different subjects for 
HMW, MMW and LMW adiponectin levels.  Abbreviations:	  O	  (Om)	  S	  (Abdsc) 	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Figure 3.  Adiponectin release from 43 
paired samples in omental and Abdsc 
(AU). Fragments of adipose tissue were 
incubated for 3hr in M199+1% BSA pH 
7.4 under 95% of Oxygen and 5% CO2 and 
adiponectin levels were determined with 
quantitative immunoblotting.  Band 
densities were quantitated using Multi 
Gauge image software. A. Total 
adiponectin secretion.  B. HMW secretion.  
C. % HMW secretion. *,  p<0.05 Om vs. 
Abdsc with paired t test. 
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Higher IL-6 secretion in Om than Abdsc adipose tissues 
Because IL-6 production by macrophages and other cell types within adipose tissue is a 
marker for inflammation, and inflammation is known to affect adipokine expression and 
release, we measured IL-6 secretion in the acute media.  IL-6 secretion was ~56% higher 
in omental compared to Abdsc (p=0.03, paired t test on log transformed values, Figure 5), 
as expected. 
 
 
Figure 5. IL-6 release (ng/g/3hr) from forty-three paired samples in omental and abdominal 
subcutaneous. Fragments of adipose tissue were incubated for 3hr in M199+1% BSA pH 7.4 
under 95% of Oxygen and 5% CO2. IL-6 levels were determined with ELISA. *, p<0.05 Om 
vs. Abdsc with paired t test. 	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(Figure 6A).  Phospho-JNK levels were also measured as a marker of tissue inflammation 
and were higher in omental than Abdsc, similar to higher IL-6 expression in the omental 
depot (Figure 6B). 
 
Figure 6. Adrx levels (AU) from nineteen paired samples in omental and Abdsc human adipose 
tissue. A. Adrx levels were measured by Western Blot and the band densities were 
quantitated using Multi Gauge image software and Adrx expression is presented as relative 
to HSP90, a loading control. The data are presented in bars indicating the mean values for 
each nineteen set of samples. *, P<0.05. B. Representative images of Western blotting from 
7 subjects. HSP90, a loading control. Expression levels of phospho-JNK are also measured 
as a marker of tissue inflammatory status.  Abbreviations: O (Om) S (Abdsc) 
 
 
Correlation of Adiporedoxin (Adrx) with adipokine release in adipose tissues 
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protein expression and adiponectin secretion in Abdsc was statistically significant (r2= 
0.23, p= 0.044).  HMW adiponectin secretion was positively correlated with Adrx protein 
levels in Abdsc and there was a positive trend in Om adipose tissues (n=19: p=0.0136 in 
Abdsc and p=0.069 in Om).  % HMW adiponectin secreted and Adrx levels were 
negatively correlated in Abdsc (p=0.0173) but not in Om (p=0.846) (Table 4 and Figure 
7). 
 
Table 4. Correlation of Adrx protein levels with adipokine release in Abdsc and Om 
in human adipose tissues. 
 
Adrx (AU)  n=19 Abdsc Om 
 
r2 p r2 p 
Leptin (ng/g/3hr) 0.0056 0.75 0.04 0.376 
Total Adiponectin (ng/g/3hr) 0.0459 0.3781 0.045 0.3829 
IL-6 (ng/g/3hr) 0.08 0.2273 0.043 0.3901 
Total adiponectin (AU) 0.1706 0.0787 0.095 0.1982 
HMW adiponectin (AU) 0.308 0.0136* 0.17 0.069 
% HMW adiponectin 0.29 0.0173* 0.002 0.846 
Simple bivariate correlation of Adrx levels in Abdsc and Om (n=19) with adipokines in both 
depots. P values are consider statistical significant with a p <0.05 
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Figure. 7: Correlation of Adrx protein levels in Abdsc and the secretion in Abdsc of total (the 
sum of HMW+MMW+LMW), HMW and % of HMW (HMW/total adiponectin) levels 
determined with Native PAGE A. Correlation between total adiponectin secretion and 
Adrx protein expression levels in Abdsc B. Correlation between total adiponectin release 
and Adrx expression levels in Abdsc with adjusted line (AU) excluding one outlier(green 
line) C. Correlation between HMW adiponectin secretion and Adrx protein expression in 
Abdsc D. Correlation between % of HMW (HMW/total adiponectin) and Adrx expression 
levels in Abdsc tissue. Red dots = females, blue triangle = males. 
 
 
Correlation of Adrx expression levels in adipose tissues and serum adipokines levels 
Adrx protein levels in Abdsc, not omental, adipose tissue tended to be negatively 
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were not correlated with Adrx protein levels in Abdsc, while tend to be positively 
correlated in Om (p=0.1116).  Total serum adiponectin, HMW and % HMW levels, 
determined by native Western blotting, were not correlated with Adrx protein levels in 
both Abdsc and Om human adipose tissues (Table 5)  
 
Table 5. Correlation of Adrx protein levels with serum adipokine levels. 
Adrx (AU)  n=11 Abdsc Om 
 r
2 p r2 p 
Leptin (ng/ml) 0.32 0.0672 0.006 0.8191 
Total Adiponectin (ng/ml) 0.16 0.2216 0.2568 0.1116 
Total adiponectin (AU) 0.222 0.6615 0.095 0.2561 
HMW adiponectin (AU) 0.037 0.5673 0.1486 0.2415 
% HMW adiponectin 0.028 0.6214 0.026 0.6336 
Simple bivariate correlation of Adrx protein levels in Abdsc and Om (n=11) with serum 
adipokine levels. P values are consider statistical significant with a p <0.05. 
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DISCUSSION 
Depot differences in Adrx protein expression levels 
It was hypothesized that Adrx, a protein highly enriched in adipocytes and ER 
resident that is likely to facilitate protein assembly and secretion would be decreased in 
omental depot compared to Absc.  Work from our lab (KK, MJL, SKF) showed that Adrx 
mRNA and protein levels in human Abdsc adipose tissue of young, healthy subjects, 
ranging in level of obesity, correlated positively with adiponectin mRNA and protein, and 
negatively with adipose tissue inflammation (as indicated by phospho-Jun kinase) in a 
statistical model in which BMI was accounted for.39 In the current study of nineteen 
paired samples of Om and Abdsc from obese men and women,  we found that Adrx 
protein expression was 1.4 fold higher in Abdsc than omental  adipose tissues. Adrx 
protein expression in Om may be lower than Abdsc, due to higher inflammation and 
higher oxidative stress, as it was previously show. 39,46 Accordingly, we found higher 
pJNK, a marker of tissue inflammation; in omental than Abdsc, but the results was not 
quantificated. 6 subjects were included and 1 was underloaded.    
The release of adipokines, leptin, adiponectin and IL-6 is known to be different 
between the two depots although reports on adiponectin releases are inconsistent. 31,35-37 
Consistent with other results in the literature34,44,45	  , leptin release was higher in Abdsc 
than omental while IL-6 was higher in omental than Abdsc.  We measured the release in 
short term incubation (3hr) of freshly obtained adipose tissue within 30 min of excision 
because it is likely to reflect the in vivo characteristics of the subjects, in contrast to 
longer-term cultures.  We also measured actual the release of adipokines rather than 
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mRNA expression or release in long-term incubations. In addition, we also expressed the 
release of leptin and adiponectin per cell number as well as gram tissue since leptin and 
adiponectin is produced by fat cells and the sizes of fat cells are different between 
adipose depots and known to affect adipokine secretion. We wanted to determine the 
adipokine secretion per fat cell to whether determine if the results from adipokine 
secretion per tissue weight were similar when it was measured with per fat cell. The 
results were attenuated. Leptin and total adiponectin were higher,in Abdsc than Om by 3 
fold and 1.8, respectively. 
The present study demonstrated that human adiponectin secretion is higher in 
Abdsc than Om adipose tissue. This finding is in contrast with previous studies by 
Kovacova et al, measured total adiponectin in adipose tissue explants incubated for 4hr, 
Drolet et al, measured total adiponectin in Abdsc and Om incubated for 2 hrs and the 
results were expressed as ng/mg lipids and Motoshima et al, measured total adiponectin 
in subcutaneous and Om incubated for 24 and 48 hrs. These three studies showed no 
depot difference in total adiponectin secretion in adipose tissue. However, Swensson et al 
showed significantly lower total adiponectin secretion in omental adipose tissue than 
Abdsc with short-time incubation (2, 4 and 6 hr). Thus, the present study confirms and 
strengthens the findings that omental secretes lower total adiponectin secretion compared 
to Abdsc.  In addition, we measured adiponectin levels using both ELISA and 
quantitative native Western blotting, and both methods results in similar data, i.e. total 
adiponectin secretion is higher in Abdsc than omental adipose tissue.    
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Adiponectin circulates in multiple isoforms, HMW, MMW, and LMW and HMW 
adiponectin correlates better with insulin sensitivity in vivo. 15, 16, 32 No previous studies 
however, examined the fat depot differences in the releases of adiponectin isoforms in 
human Abdsc versus omental adipose tissues.  Using native polyacrylamide gel 
electrophoresis and quantitative immunoblotting, we compared the secretion of 
adiponectin multimers between the two depots.  Similar to ELISA data, total adiponectin 
secretion was higher in Abdsc than omental adipose tissue.  The secretion of HMW 
isoform as well as the % HMW however, was higher in Om than Abdsc. These results 
were not expected since it was hypothesized that HMW and % HMW would be higher in 
Abdsc than omental, since total adiponectin was higher in the former depots.  In addition, 
because Adrx was higher in Abdsc and Adrx plays a role in the assembly of the disulfide 
bonds of the adipokine, adiponectin, it was thought that the secretion of HMW would be 
higher in Abdsc than omental adipose tissue.  
 
Adrx correlation with adipokine release from human Om and Absc adipose tissue 
To understand the relationship between Adrx protein expression and adipokine release in 
human Abdsc and omental adipose tissue, we tested whether Adrx protein levels were 
correlated with adipokines release.  Leptin secretion and IL-6 secretion were not 
statistically significantly correlated with Adrx expression in either depot. It was expected 
that Adrx levels in adipose tissue would be positively correlated with total adiponectin, 
HMW and % HMW in both depots.  Adrx protein levels were not correlated with total 
adiponectin measured by ELISA in both depots. Adrx protein levels positively correlated 
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with total and HMW adiponectin measured by Western blotting in Abdsc adipose tissue.  
Total adiponectin in Abdsc measured with Western blot was not statistically significant 
although there was a positive trend with a p value close to 0.05. When one outlier was 
excluded from the analysis, the correlation became statistically significant.  Total 
adiponectin and HMW was positively correlated with Adrx levels in Abdsc. However, 
Om showed no correlation with total adiponectin, however a positive trend was shown 
with HMW but it was not statistically significant since the p value was close to 0.05. % 
HMW secretion was negatively correlated to Adrx levels in Abdsc. Om showed no 
correlation between Adrx protein expression and % HMW in both depots. This result was 
unexpected because Adrx play a role in the formation of disulfide bond of adiponectin, 
we hypothesized that total adiponectin, HMW and % HMW will be positively correlated.  
It may be that Adrx increases the production of LMW (trimmers) and MMW (hexamers) 
but not as much as HMW (increased in the production of LMW and MMW by 30% but 
the production of HMW is 20% lower in Abdsc than Om). There may be another enzyme 
or a regulatory step between MMW and HMW that play roles in the assembly of HMW 
adiponectin. 
 
Adrx levels in Abdsc and omental adipose tissue did not correlate with serum 
adipokine levels. 
Data from our lab found that knockdown of Adrx in human adipocytes decreased 
all isoforms of adiponectin secretion from Abdsc incubations, while increasing leptin 
secretion (unpublished data KK MJ SKF ).  C57BL/6J wild type mice exposed to high fat 
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diet showed decreased cellular Adrx and decreased circulating HMW adiponectin and 
Adrx knockout mice presented higher cellular adiponectin retention and lower circulating 
adiponectin levels (unpublished data).  Based on these data we hypothesized that Adrx 
levels in Abdsc and omental would be positively correlated with total, HMW and % 
HMW adiponectin in serum. Thus, we determined whether adipose Adrx protein levels 
correlates with circulating levels of adipokines.  The relationship between Adrx levels 
and the circulating adipokines in serum were not statistically significant.  Circulating 
leptin levels, a maker of adiposity, have a negative trend to Adrx protein levels in Abdsc 
but there was not a trend with Adrx expression in Om. Total adiponectin in serum 
measured by ELISA were not correlated with Adrx levels in Abdsc while it showed a 
positive trend with Adrx levels in Om. The result with no correlation between circulating 
total adiponectin and Adrx protein levels in Abdsc are unexpected because the assembly 
of total adiponectin should be correlated with Adrx. However, the small sample size 
limits this analysis, and many factors that could affect adiponectin production were not 
assessed (e.g. inflammation, redox stress, body fat distribution). We also did not have 
sufficient numbers to assess the effect of sex and only studied obese subjects so the range 
of values was likely limited.  Total adiponectin and HMW levels measured with 
quantitative Western blotting were not correlated with Adrx expression in Abdsc and Om.  
As well as the % HMW were not correlated with Adrx expression in either depots.  
The differences between the results in total adiponectin measured by ELISA and 
Western Blot could be explained because Western Blot is a more sensitive assay than 
ELISA and we measured multiple isoforms with Western blotting, and the findings are 
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more exact with Western Blot than ELISA. To determine if the values were close enough 
we run a correlation between total adiponectin measured by ELISA and Western blotting 
and showed a positive correlation. We did tried to measure adiponectin multimers in 
serum with ELISA but got strange results because the % HMW was higher > 100% in 
most of the samples, did not make any sense. Also, it is not possible to use HMW 
multimer with ELISA kit in secretion media. So we decided to run the Western blotting 
for adiponectin isoforms.   
Our results suggest that the assembly of HMW is not 100% controlled by Adrx 
and other proteins may play a role. In addition, the number of samples used in correlation 
studies was small, and most of our subjects were severely obese. It would be better to 
determine a relationship with a bigger sample size and wide range of subjects. We did not 
find positive correlation between Adrx protein levels and total adiponectin in Abdsc 
measured with ELISA although there was a positive trend, possibly due to a small sample 
size.  
In conclusion, we have provided evidence that in obese subjects, depot 
differences in Adrx expression, lower in omental vs. Abdsc, may influence depot 
differences in adipokine secretion. Adrx may play a role in the assembly of LMW and 
MMW rather than HMW, since it was found that % HMW was negatively correlated with 
Adrx while there was a trend for total adiponectin secretion. The mechanism of higher 
HMW and % HMW in omental with lower Adrx levels needs further study, but appears 
to be related to depot differences in inflammation and oxidative stress (as indicated by 
JNK-P). 
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Limitations of the study 
In the current study, one limitation was the sample size for Adrx levels (n=19) 
and when the correlation was calculated with adipokine release and serum the sample 
size was even smaller (n=11). Also, only obese subjects, mostly female, were included in 
this study.  Another limitation is that the diabetic subjects some of them were classified 
as “diabetic” but some of them had a normal blood glucose levels, normal HbA1c and 
some of them did not have any medication for diabetes.  
For future studies, a bigger sample size with same number of females and males 
including a variable range of BMI to determine sex differences and non-obese vs. obese 
in depot for Adrx expression and adipokine secretion will be required. In addition, a 
better analysis of the diabetic subjects, looking for more information about each diabetic 
subject, such as date of diagnosis, laboratories results, all medication listed for the day of 
the sample collection.  
 
Future directions 
As it is well known from the current study, Adrx levels are different between 
depots, i.e. higher in Abdsc than omental. It would be interesting to determine sex 
differences in Adrx expression levels as there are sex-dependent differences in leptin and 
adiponectin levels, and analyze the relationship between Adrx protein expression levels 
and phospho-JNK in the Western Blots. We are currently investigating this. It would be 
also interesting to do the correlation of Adrx expression with the other adiponectin 
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isoforms (MMW and LMW) to determine why the % HMW is negative correlated with 
Adrx and if there is another molecule playing a role in the conversion of MMW to HMW.  
The unexpected results between the negative correlation with Adrx in Abdsc and %HMW 
needs to be analyze more carefully.  
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